atorvastatin has been researched along with Renal Insufficiency in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Duan, Q; Peng, X; Wang, J; Wang, Z; Xia, F | 1 |
| Atighi, E; Babapour, B; Hosseninia, S; Mohammadi Kebar, S | 1 |
| Ahn, CW; Cha, BS; Cho, Y; Choe, EY; Huh, KH; Kang, ES; Kim, MS; Kim, YS; Kwon, O; Lee, HC; Wang, HJ | 1 |
| Braunwald, E; Cannon, CP; Daga, S; Dalby, AJ; Eisen, A; Goodrich, EL; Im, K; Lukas, MA; O'Donoghue, ML; Spinar, J; Steen, DL; Zhou, J | 1 |
| Deedwania, P; Singh, V | 1 |
| Arisz, L; Kastelein, JJ; Koopman, MG; Ozsoy, RC | 1 |
| Abel, RB; Horton, M; Moore, S; Olson, SC; Stern, RH; Yang, BB | 1 |
1 review(s) available for atorvastatin and Renal Insufficiency
| Article | Year |
|---|---|
Expanding roles for atorvastatin.
Topics: Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Renal Insufficiency; Stroke | 2008 |
1 trial(s) available for atorvastatin and Renal Insufficiency
| Article | Year |
|---|---|
Preventive Effects of Nicorandil and Atorvastatin in Contrastinduced Nephropathy in Patients with Renal Dysfunction Undergoing Coronary Artery Angiography: A Double Blind, Randomized, Controlled Clinical Trial.
Topics: Atorvastatin; Coronary Angiography; Coronary Vessels; Humans; Nicorandil; Renal Insufficiency; Renal Insufficiency, Chronic | 2023 |
5 other study(ies) available for atorvastatin and Renal Insufficiency
| Article | Year |
|---|---|
Atorvastatin reduces renal interstitial fibrosis caused by unilateral ureteral obstruction through inhibiting the transcriptional activity of YAP.
Topics: Animals; Atorvastatin; Fibrosis; Mice; Renal Insufficiency; Renal Insufficiency, Chronic; Ureteral Obstruction | 2023 |
HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Dyslipidemias; Fasting; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Immunosuppressive Agents; Incidence; Indoles; Kidney Transplantation; Male; Middle Aged; Pyrroles; Renal Insufficiency | 2014 |
Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Atorvastatin; Benzaldehydes; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Oximes; Phospholipase A2 Inhibitors; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Renal Insufficiency; Rosuvastatin Calcium; Secondary Prevention; Sex Factors; Simvastatin | 2017 |
Atorvastatin and the dyslipidemia of early renal failure.
Topics: Adolescent; Adult; Aged; Atorvastatin; Body Mass Index; Cholesterol, LDL; Combined Modality Therapy; Creatinine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Linear Models; Male; Middle Aged; Pyrroles; Renal Insufficiency; Risk Factors; Treatment Outcome | 2003 |
Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Renal Insufficiency | 1997 |